← Eichor
Study identifier: NCT04642430 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Condition: Atrial Fibrillation  ·  Sponsor: Ottawa Hospital Research Institute

PhasePhase 4
Planned participants3018
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be fatal. A stroke occurs when blood flow to the brain is blocked by a clot, depriving brain cells of oxygen. In people with atrial fibrillation, blood flow is sluggish in the top chambers of the heart, and blood clots can form there. When a piece of a clot breaks off, it can travel to the brain and cause a stroke. That's where blood thinners come in. Blood thinners, or anticoagulants, decrease the chances of blood clots forming in the heart, reducing the risk of stroke. Studies show that blood thinners are highly effective at reducing the risk of stroke by up to 95%. The conventional blood thinner is warfarin, taken by mouth. Warfarin requires regular blood tests to make sure a patient getting the correct dose. The patient also may have to avoid certain foods since the medication can interact with them. Newer blood thinners, known as direct-oral anticoagulants (DOACs) are available, which do not require regular blood tests and do not interact with foods. Two of the new blood thinners are called rivaroxaban and apixaban. Like warfarin, they can be taken by mouth, and studies have shown them to be as effective as warfarin. Both rivaroxaban and apixaban have been approved for stroke prevention in AF by He…

This description comes directly from the study's public registry record.

Talk to the study team

Lana Castellucci, MD, FRCPC  ·  613-737-8899  ·  lcastellucci@toh.ca

Erin Thomas  ·  613-737-8899  ·  erithomas@toh.ca

Always discuss trial participation with your own doctor first.

Locations (8)

Victoria Cardiac Arrhythmia TrialsVictoria, British Columbia, CanadaRecruiting
QEII Health Science CentreHalifax, Nova Scotia, CanadaRecruiting
Kingston General HospitalKingston, Ontario, CanadaRecruiting
The Ottawa Hospital - General CampusOttawa, Ontario, CanadaRecruiting
University Ottawa Heart InstituteOttawa, Ontario, CanadaRecruiting
CISSS de l'OutaouaisGatineau, Quebec, CanadaRecruiting
CHU de Quebec - Université LavalLaval, Quebec, CanadaNot Yet Recruiting
Ciusss NimMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04642430